Gadoversetamide

Gadoversetamide
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Routes of
administration		Intravenous
ATC code
Pharmacokinetic data
Protein bindingNil
MetabolismNil
Elimination half-life80 to 120 minutes
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H34GdN5O10
Molar mass661.77 g·mol−1
3D model (JSmol)
  • [Gd+3].O=C(NCCOC)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(=O)NCCOC)CC([O-])=O
  • InChI=1S/C20H37N5O10.Gd/c1-34-9-3-21-16(26)11-24(14-19(30)31)7-5-23(13-18(28)29)6-8-25(15-20(32)33)12-17(27)22-4-10-35-2;/h3-15H2,1-2H3,(H,21,26)(H,22,27)(H,28,29)(H,30,31)(H,32,33);/q;+3/p-3 checkY
  • Key:HBEAOBRDTOXWRZ-UHFFFAOYSA-K checkY
 ☒NcheckY (what is this?)  (verify)

Gadoversetamide is a gadolinium-based MRI contrast agent, particularly for imaging of the brain, spine and liver.[1][2] It is marketed under the trade name OptiMARK.

Notes

  1. ^ "Gadoversetamide Drug Information". Drugs.com. 2000-03-20. Archived from the original on 2007-10-10. Retrieved 2007-03-23.
  2. ^ Cheng KT (10 December 2007). "Gadoversetamide: Gd-DTPA-BMEA". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641436.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about magnetic resonance imaging is a stub. You can help Wikipedia by expanding it.